GH 57
Alternative Names: GH-57Latest Information Update: 22 Jun 2022
At a glance
- Originator Suzhou Genhouse Bio
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Jun 2022 Discontinued for Cancer in China (unspecified route) (Suzhou Genhouse Bio pipeline, June 2022)
- 01 Sep 2021 GH 57 is available for licensing as of 26 Aug 2021. https://www.genhousebio.com/en/cooperation/index.html
- 26 Aug 2021 Early research in Cancer in China (unspecified route) before August 2021 (Suzhou Genhouse Bio pipeline, August 2021)